Health News Digest: Legal Battles, Bird Flu, and Pharma Shifts

This summary covers recent developments in health, including Novo Nordisk filing lawsuits against semaglutide compounders, bird flu affecting Brazilian chicken trade, and Novartis exploring a takeover of Avidity Biosciences. The US imposes tariffs on pharmaceutical imports, FDA approving Jazz Pharma's new cancer drug, and concern over Gaza's severe water crisis are also highlighted.

In the world of health, Danish drugmaker Novo Nordisk escalates its legal battle against compounding companies by filing 14 new lawsuits targeting unapproved versions of semaglutide. These companies allegedly offer personalized doses of the ingredient found in popular drugs Wegovy and Ozempic.

Meanwhile, Brazil grapples with trade restrictions following a bird flu outbreak affecting its status as the world's largest chicken exporter. With the nation declaring itself virus-free in commercial flocks, some import bans are being reversed.

In pharmaceuticals, Novartis has reportedly approached Avidity Biosciences for a potential acquisition. Trump plans to increase tariffs on pharmaceutical imports to boost domestic production, while the FDA approves Jazz Pharma's drug for a rare brain tumor.

(With inputs from agencies.)